Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

SRR1473822

GTEX

ab736c22-ae52-5853-949e-8056e668f4d8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
—
subtype
—
cancer_type
GTEX
sex
Female

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.419
  • COAGULATION+0.416
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.371
  • MYOGENESIS+0.340
  • BILE_ACID_METABOLISM+0.283
  • ESTROGEN_RESPONSE_LATE+0.258
  • INFLAMMATORY_RESPONSE+0.241
  • XENOBIOTIC_METABOLISM+0.225
  • PANCREAS_BETA_CELLS+0.224
  • ALLOGRAFT_REJECTION+0.204

Top 10 suppressed

  • PROTEIN_SECRETION-0.486
  • MYC_TARGETS_V2-0.477
  • MYC_TARGETS_V1-0.467
  • DNA_REPAIR-0.447
  • UNFOLDED_PROTEIN_RESPONSE-0.430
  • MITOTIC_SPINDLE-0.415
  • TGF_BETA_SIGNALING-0.403
  • WNT_BETA_CATENIN_SIGNALING-0.332
  • G2M_CHECKPOINT-0.318
  • CHOLESTEROL_HOMEOSTASIS-0.316

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1392725
brain-umap@2
GTEX—0.954
2SRR1431229
brain-umap@2
GTEX—0.946
3SRR1443955
brain-umap@2
GTEX—0.943
4SRR1432765
brain-umap@2
GTEX—0.939
5SRR1366961
brain-umap@2
GTEX—0.929
6SRR1321552
brain-umap@2
GTEX—0.926
7SRR1476571
brain-umap@2
GTEX—0.924
8SRR1455698
brain-umap@2
GTEX—0.922
9SRR1475022
brain-umap@2
GTEX—0.921
10ERR2598288
medullo-epn-umap@date-based
fetalfetal0.920

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.419Remibrutinib— uncovered
COAGULATION0.416Binimetinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.371Inavolisib— uncovered
MYOGENESIS0.340Inavolisib— uncovered
BILE_ACID_METABOLISM0.283Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.258Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.241Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.225Inavolisib— uncovered
PANCREAS_BETA_CELLS0.224Cobimetinib— uncovered
ALLOGRAFT_REJECTION0.204Idelalisib— uncovered
ANGIOGENESIS0.174Remibrutinib— uncovered
SPERMATOGENESIS0.170Inavolisib— uncovered
COMPLEMENT0.147Inavolisib— uncovered
KRAS_SIGNALING_UP0.144Inavolisib— uncovered
HYPOXIA0.138Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.136Inavolisib— uncovered
FATTY_ACID_METABOLISM0.135Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.134Inavolisib— uncovered
APICAL_SURFACE0.111Temsirolimus— uncovered
IL6_JAK_STAT3_SIGNALING0.054Inavolisib— uncovered